Panacos Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PANC research report →
Companywww.panacos.com
Panacos Pharmaceuticals, Inc. , a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company's discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion.
- CEO
- John R. Barr
- IPO
- 2005
- Employees
- 41
- HQ
- Watertown, US
Price Chart
Valuation
- Market Cap
- $5.37K
- P/E
- -0.00
- P/S
- 0.03
- P/B
- 0.00
- EV/EBITDA
- 0.49
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- 21678.89%
- Net Margin
- -20810.56%
- ROE
- -85.57%
- ROIC
- 0.00%
Growth & Income
- Revenue
- $180.00K · -36.62%
- Net Income
- $-37,459,000 · 1.71%
- EPS
- $-0.70 · 6.67%
- Op Income
- $39.02M
- FCF YoY
- -3.10%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -58.99
- Avg Volume
- 109.6
Get TickerSpark's AI analysis on PANC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 19, 08 | Fischer Laurent | other | 15,000 |
| Jun 19, 08 | LERNER IRWIN | other | 15,000 |
| Jun 19, 08 | FLETCHER R JOHN | other | 15,000 |
| Jun 19, 08 | Savage Robert G. | other | 15,000 |
| Jun 19, 08 | LIMBER JOSEPH M | other | 15,000 |
| Apr 30, 08 | DUNTON ALAN W | buy | 100,000 |
| Apr 30, 08 | DUNTON ALAN W | other | 100,000 |
| Feb 13, 08 | DUNTON ALAN W | other | 100,000 |
| Feb 13, 08 | DUNTON ALAN W | other | 150,000 |
| Feb 13, 08 | DUNTON ALAN W | other | 37,500 |
Our PANC Coverage
We haven't published any research on PANC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PANC Report →